We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Illumina

Illumina develops, manufactures and markets integrated systems for the analysis of genetic variations and biological ... read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Pediatric Acute Lymphoblastic Leukemia Monitored by DNA Sequencing

By LabMedica International staff writers
Posted on 26 Apr 2022
Print article
Image: Bone marrow aspirate of a pediatric patient with acute lymphoblastic leukemia (Photo courtesy of St. Jude Children’s Research Hospital)
Image: Bone marrow aspirate of a pediatric patient with acute lymphoblastic leukemia (Photo courtesy of St. Jude Children’s Research Hospital)

Blood plasma sequencing appears to offer a noninvasive method for tracking disease clearance or persistence in children with acute lymphoblastic leukemia (ALL), along with the presence or absence of potentially infectious microbes.

ALL is the most common pediatric cancer and, despite marked improvements in outcomes over the past 50 years, remains one of the leading causes of pediatric cancer–associated morbidity and mortality Cell-free DNA (cfDNA) sequencing has shown promise as a noninvasive diagnostic tool for evaluating maternal and child health, detecting cancer earlier and monitoring treatment response.

Pediatricians at the Stanford University School of Medicine (Stanford, CA, USA) profiled 168 blood plasma and bone marrow samples collected over six weeks from 20 children (eight females and 12 males; average age, 7.9 years) going through inductive chemotherapy treatment for ALL. The sample workflow involved DNA extraction, followed by sequencing of libraries prepared through direct ligation and capture-based enrichment using a custom panel.

Cell-free DNA (cfDNA) was quantified with a Qubit dsDNA High Sensitivity Kit (Thermo Fisher Scientific, Waltham, MA, USA). Whole-exome sequencing (WES) was performed with the xGen Exome Research Panel (Integrated DNA Technologies, Coralville, IA, USA) that consists of 429,826 probes spanning 39 Mb (19,396 genes) of the human genome covering 51 Mb of end-to-end tiled probe space. Sequencing was performed on the NextSeq instrument (Illumina, San Diego, CA, USA). The targeted sequencing data contained reads from both the ALL and microbe panels.

The investigators identified at least one circulating DNA (ctDNA) variant in all but three of the pediatric ALL patients profiled at the time of diagnosis. Most of the variants also turned up in corresponding bone marrow samples, though distinct alterations were also detected in the blood and the bone marrow. By the end of induction therapy treatment, four of the patients had minimal residual disease detectable by conventional flow cytometry-based measurements of persistent cancer cells, the team reported, while other patients appeared MRD-free but continued to carry disease-related variants in the blood.

With their microbe capture, sequencing, and detection pipeline, meanwhile, the investigators searched for potentially risky bacterial, and fungal species within cells and in cell-free DNA, comparing the microbial cell-free DNA profiles with those found in five healthy control individuals and five individuals being treated for acute myeloid leukemia. Among other microbial patterns, the team found that cell-free microbial DNA in blood plasma samples from the pediatric ALL cases fluctuated over the course of treatment.

Even so, many of the same bacterial culprits tended to turn up in the same individuals over time, including dominant microbial species not found in cancer-free control individuals. Cutibacterium was detected in most ALL samples but none of the healthy controls, which may represent the ability of the commensal skin bacteria to invade the human host. On the other hand, viral species appeared more prone to change as children experienced immune suppression related to the chemotherapy treatment.

Charles Gawad, MD, PhD, a Pediatric Oncologist and senior author of the study said, “Being able to monitor both the disease and patient-infectome interface provides a new vantage point from which we can monitor our patients. Infectious complications are the leading cause of early death and treatment changes in children with leukemia.”

The authors concluded that they had demonstrated that a customized hybrid capture [next-generation sequencing] panel can noninvasively measure the two leading causes of mortality in pediatric patients with ALL: leukemic disease burden and the invasion of infectious microbes. The study was published on April 20, 2022 in the journal Science Advances.

Related Links:
Stanford University School of Medicine 
Thermo Fisher Scientific 
Integrated DNA Technologies 
Illumina 

Gold Supplier
COVID-19 NAb Test Solution
COVID-19 NAb Test Solution
New
Silver Supplier
Anti-Müllerian Hormone (AMH) ELISA Test
PCOCheck ELISA (CE)
New
Silver Supplier
3-Part Diff Hematology Analyzer
Abacus Junior 30
New
Gold Supplier
Immunofluorescence Incubator
RaFIA Immunofluorescence Incubator

Print article

Channels

Clinical Chem.

view channel
Image: The analysis pipeline used to investigate associations between blood metabolites, later life brain imaging measures, and genetic risk for Alzheimer’s disease (Photo courtesy of University College London)

Lipid Measurements Show Potential as Alzheimer’s Disease Biomarkers

Brain changes accompanying ageing are varied and can include pathologies that lead to cognitive impairment, the commonest of which is Alzheimer’s disease (AD). Identifying blood-based signatures of brain... Read more

Molecular Diagnostics

view channel
Image: Guidance UTI provides personalized results in less than one day from receipt at lab (Photo courtesy of Pathnostics)

Rapid Result Test for Complicated Urinary Tract Infections Proves Superior to Standard Urine Culture

Complicated urinary tract infections (cUTIs) are a significant burden on individual health and healthcare resources that must be diagnosed and treated early and accurately to reduce the risk of poor outcomes.... Read more

Industry

view channel
Image: Sales of lateral flow assays in clinical testing are expected to register a CAGR of 5% through 2032 (Photo courtesy of Pexels)

Global Lateral Flow Assays Market to Surpass USD 11.5 Billion by 2032 Due to Evolving Applications

The global lateral flow assays market was valued at USD 7.2 billion in 2021 and is projected to register a CAGR of 4.7% during 2022-2032 to surpass USD 11.7 billion by the end of 2032, driven by the growing... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.